Vor Biopharma Snags $110 Million to Advance AML Treatment into the Clinic

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 7, 2020 at 8:22 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Vor Biopharma secured $110 million in a Series B financing round that will be used to advance the company’s lead stem cell-based oncology asset into clinical trials against Acute Myeloid Leukemia and other hematological cancer targets, as well as expand the company’s development portfolio.

    article source